On September 16, 2013 : Affimed Therapeutics AG and The Leukemia & Lymphoma Society (LLS) reported a partnership to co-fund a phase 2 trial with the Recruit – TandAb AFM13, a novel tetravalent bispecific antibody directed against human CD30 and CD16A in Hodgkin Lymphoma (HL) patients for whom currently available treatment s have failed (Press release, Affimed Therapeutics, SEP 16, 2013, View Source [SID:SID1234515605]). AFM13 is a first – in – class immunotherapy drug designed to treat HL patients and patients with CD30 – positive malignancies . LLS has committed to investing up to $4.4 million over 2 years to support the project.
Dr . Richard Winneker, SVP Research for LLS , stated, " Though the cure rate for Hodgkin Lymphoma is high compared to other types of blood cancers , refractory and relapse d patients have few therapeutic options . More importantly current treatments for HL patients involve cytotoxic drug therapies and radiotherapy , which are likely responsible for secondary tumors and other considerable long term side effects developing later in a patient ’ s life , leaving open a critical need for safer and more durable therapies. LLS is committed to advancing breakthrough therapies, particularly for patients with unmet medical need s, and Affimed’s immunotherapy is emerging as a promising thera peutic option for HL patients . "
"The partnership between Affimed and LLS is a significant validation of the high potential of our TandAb platform and reinforces our strategy to develop this novel bispecific construct for hematological tumors", said Dr. Adi Hoess, CEO of Affimed AG. "We very much welcome LLS ’s commitment to AFM13 , and we look forward to an accelerated de velopment of this therapy for patients with limited treatment options to date."
In a phase 1 trial , AFM13 has shown a good safety profile , as it was well tolerated at all dose levels tested. Furthermore, AFM13 showed clear and meaningful signs of efficacy in some patients deemed to have a poor prognosis, including patients who had not benefited from the recently approved CD30 targeting drug , brentuximab vedotin ( Adcetris , Seattle Genetics). These encouraging data warrant the further investigation of AFM13 in a phase 2 trial to further assess its efficacy. Moreover, these trials could provide proof of concept for using bispecific antibodies to elicit natural killer (NK) cells, vital lymphocytes of the innate immune system, to effectively kill cancer cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!